Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$303M |
| 2 |
General Dynamics
GD
|
+$147M |
| 3 |
Cigna
CI
|
+$95.5M |
| 4 |
CVS Health
CVS
|
+$85.5M |
| 5 |
Marathon Petroleum
MPC
|
+$52.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$234M |
| 2 |
Northrop Grumman
NOC
|
+$218M |
| 3 |
ESRX
Express Scripts Holding Company
ESRX
|
+$170M |
| 4 |
PX
Praxair Inc
PX
|
+$168M |
| 5 |
COL
Rockwell Collins
COL
|
+$116M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.9% |
| 2 | Healthcare | 16.26% |
| 3 | Consumer Discretionary | 11.53% |
| 4 | Communication Services | 10.15% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TDAY
1951
USA Today Co
TDAY
$1B
| $1.09M | ﹤0.01% |
94,662
| – | – |
|
|
ORIT
1952
DELISTED
Oritani Financial Corp. New
ORIT
| $1.09M | ﹤0.01% |
74,200
-1,500
| -2% | -$22.6K |
|
1953
BioCryst Pharmaceuticals
BCRX
$2.5B
| $1.09M | ﹤0.01% |
135,400
+15,400
| +13% | +$120K |
|
|
CMO
1954
DELISTED
Capstead Mortgage Corp.
CMO
| $1.09M | ﹤0.01% |
163,800
| – | – |
|
1955
Puma Biotechnology
PBYI
$451M
| $1.09M | ﹤0.01% |
53,830
+1,900
| +4% | +$57K |
|
|
SPTN
1956
DELISTED
SpartanNash
SPTN
| $1.09M | ﹤0.01% |
63,580
-1,300
| -2% | -$23.6K |
|
1957
Onto Innovation
ONTO
$20.8B
| $1.09M | ﹤0.01% |
39,900
| – | – |
|
1958
Encore Capital Group
ECPG
$2.14B
| $1.09M | ﹤0.01% |
46,300
| – | – |
|
1959
QuinStreet
QNST
$1.19B
| $1.08M | ﹤0.01% |
66,700
+2,300
| +4% | +$34.6K |
|
1960
Tidewater
TDW
$4.51B
| $1.08M | ﹤0.01% |
56,600
+17,400
| +44% | +$453K |
|
|
INFN
1961
DELISTED
Infinera Corporation Common Stock
INFN
| $1.08M | ﹤0.01% |
270,500
+12,100
| +5% | +$60.7K |
|
|
HSKA
1962
DELISTED
Heska Corp
HSKA
| $1.08M | ﹤0.01% |
12,500
| – | – |
|
|
ORBC
1963
DELISTED
ORBCOMM, Inc.
ORBC
| $1.07M | ﹤0.01% |
130,000
| – | – |
|
1964
Addus HomeCare
ADUS
$2.2B
| $1.07M | ﹤0.01% |
15,800
+1,700
| +12% | +$116K |
|
1965
AMC Entertainment Holdings
AMC
$2.33B
| $1.07M | ﹤0.01% |
8,694
-380
| -4% | -$62.2K |
|
|
NFBK
1966
DELISTED
Northfield Bancorp
NFBK
| $1.07M | ﹤0.01% |
78,800
+2,200
| +3% | +$30.5K |
|
1967
Origin Bancorp
OBK
$1.68B
| $1.07M | ﹤0.01% |
+31,282
| New | +$1.14M |
|
|
ENLC
1968
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $1.06M | ﹤0.01% |
112,123
+2,000
| +2% | +$25.8K |
|
1969
M/I Homes
MHO
$3.87B
| $1.06M | ﹤0.01% |
50,500
+2,400
| +5% | +$55.4K |
|
1970
Lantheus
LNTH
$6.58B
| $1.06M | ﹤0.01% |
67,700
+1,800
| +3% | +$27.6K |
|
|
NVEE
1971
DELISTED
NV5 Global
NVEE
| $1.06M | ﹤0.01% |
70,000
+2,400
| +4% | +$44.5K |
|
1972
Enova International
ENVA
$6.58B
| $1.06M | ﹤0.01% |
54,400
+1,600
| +3% | +$36.4K |
|
1973
Fortuna Silver Mines
FSM
$3.1B
| $1.06M | ﹤0.01% |
288,700
+11,400
| +4% | +$42.1K |
|
|
FSCT
1974
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
| $1.06M | ﹤0.01% |
40,700
+2,200
| +6% | +$60.9K |
|
1975
German American Bancorp
GABC
$1.92B
| $1.05M | ﹤0.01% |
37,950
| – | – |
|
Similar funds
Swiss National Bank's Q4 2018 Portfolio in Review
As of Q4 2018, Swiss National Bank held 2,591 positions worth $78B, down 13% from $89.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Swiss National Bank's Q4 2018 filing shows 87 new, 1,610 increased, 323 reduced and 55 closed positions. Its largest new stake was Linde: 1,915,836 shares worth $299M. The largest sale was Aetna Inc, an estimated $234M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Swiss National Bank's largest Q4 2018 buy was Linde: 1,915,836 shares worth $299M.
- Swiss National Bank added most to Cigna in Q4 2018, an estimated $95.5M increase.
- Swiss National Bank's biggest Q4 2018 reduction was Dell, cutting an estimated $52.3M.
- Swiss National Bank fully exited Aetna Inc in Q4 2018, selling an estimated $234M.
- Swiss National Bank's ten largest holdings make up 18% of its $78B portfolio in Q4 2018.
- Swiss National Bank opened 87 new positions and closed 55 in Q4 2018.
- Swiss National Bank's portfolio value fell 13% quarter-over-quarter to $78B.
Based on Swiss National Bank's 13F filing for Q4 2018, filed 13 Feb 2019.